Your session is about to expire
← Back to Search
Chatbot for Hereditary Cancer Risk Assessment
N/A
Recruiting
Led By Melissa K Frey, MD
Research Sponsored by Weill Medical College of Cornell University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights
Study Summary
This trial will compare a mobile health platform that uses artificial intelligence and natural language processing (a 'chatbot') to usual care in order to determine if the chatbot system can improve rates of recommendation for genetic testing among patients at elevated risk of familial cancer syndrome in an all-Medicaid gynecology clinic.
Who is the study for?
This trial is for individuals aged 18 or older who are new patients at a gynecology clinic, speak and read English, and have access to text messaging on a phone. They should not have had genetic testing for hereditary cancer syndromes before.Check my eligibility
What is being tested?
The study tests if a chatbot using artificial intelligence can increase recommendations for genetic testing in patients at high risk of familial cancer syndromes compared to the usual care in an all-Medicaid gynecology clinic.See study design
What are the potential side effects?
Since this intervention involves communication via a chatbot, there are no direct physical side effects like those associated with medications or surgeries. However, participants may experience stress or anxiety related to discussing their genetic risks.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 2 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Genetic screening method
Secondary outcome measures
Genetic screening method
Facilitator of inequity in the utilization of genetic services
Genetic screening method
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: ChatbotExperimental Treatment1 Intervention
Subjects will receive a text message initiating a chatbot conversation that relies on natural language processing to gather personal and family cancer. Subjects are identified by the chatbot as meeting National Comprehensive Cancer Network (NCCN) high-risk criteria. Next, subjects undergo pre-test genetic counseling via the chatbot and then clinicians are notified (via the chatbot portal) that the subject meets high-risk criteria. For subjects meeting high-risk criteria (based on the chatbot evaluation), the clinician will complete genetic counseling and recommend genetic testing during the visit. For subjects interested in genetic testing, the clinician will order genetic testing.
Group II: Usual CareActive Control1 Intervention
Personal and family cancer history will be collected by the clinician during the subject's visit. Clinicians will evaluate the patient's personal/family history according to National Comprehensive Cancer Network (NCCN) high-risk criteria. For subjects recognized by the clinician as meeting NCCN criteria, the clinician will complete genetic counseling and recommend genetic testing. For subjects interested in genetic testing, the clinician will order genetic testing.
Find a Location
Who is running the clinical trial?
Weill Medical College of Cornell UniversityLead Sponsor
1,055 Previous Clinical Trials
1,316,144 Total Patients Enrolled
Melissa K Frey, MDPrincipal InvestigatorWeill Medical College of Cornell University
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am younger than 18 years old.I have undergone genetic testing for cancer syndromes.I have never had genetic testing for cancer syndromes.I cannot read or speak English.I am 8 years old or older.
Research Study Groups:
This trial has the following groups:- Group 1: Chatbot
- Group 2: Usual Care
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Are there any vacancies available in this experiment for participants?
"According to the clinicaltrials.gov database, this medical investigation is no longer seeking participants. Initially posted on October 1st 2022 and last edited a few days ago (September 27th), it has concluded its recruitment efforts but there are still 77 other studies actively enrolling patients at present."
Answered by AI
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger